OptimizeRx (NASDAQ:OPRX) Upgraded to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of OptimizeRx (NASDAQ:OPRX) from a buy rating to a strong-buy rating in a research note released on Saturday.

A number of other analysts have also recently weighed in on the company. Roth Capital reiterated a “buy” rating on shares of OptimizeRx in a research report on Friday, August 8th. JMP Securities increased their price objective on shares of OptimizeRx from $20.00 to $23.00 and gave the company a “market outperform” rating in a report on Friday, October 10th. Stifel Nicolaus upped their target price on shares of OptimizeRx from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Friday, August 8th. Citizens Jmp lifted their price objective on OptimizeRx from $23.00 to $24.00 and gave the company a “market outperform” rating in a report on Friday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of OptimizeRx in a research note on Wednesday, October 8th. Nine research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $14.45.

OptimizeRx Price Performance

Shares of NASDAQ:OPRX opened at $15.65 on Friday. The company’s fifty day moving average is $18.87 and its two-hundred day moving average is $15.15. The company has a quick ratio of 2.57, a current ratio of 2.57 and a debt-to-equity ratio of 0.21. The company has a market cap of $290.54 million, a P/E ratio of -28.98 and a beta of 1.24. OptimizeRx has a 12-month low of $3.78 and a 12-month high of $22.25.

OptimizeRx (NASDAQ:OPRX) last issued its earnings results on Thursday, November 6th. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.17. The firm had revenue of $26.07 million for the quarter, compared to the consensus estimate of $23.83 million. OptimizeRx had a positive return on equity of 4.50% and a negative net margin of 9.42%. OptimizeRx has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. Equities analysts expect that OptimizeRx will post -0.33 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Stephen L. Silvestro sold 1,620 shares of the firm’s stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $18.75, for a total transaction of $30,375.00. Following the transaction, the chief executive officer directly owned 188,916 shares of the company’s stock, valued at $3,542,175. This trade represents a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Patrick D. Spangler sold 11,120 shares of the company’s stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $17.49, for a total value of $194,488.80. Following the completion of the transaction, the director owned 44,215 shares of the company’s stock, valued at $773,320.35. This trade represents a 20.10% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 5.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC increased its holdings in shares of OptimizeRx by 600.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock worth $29,000 after buying an additional 1,818 shares during the last quarter. Quantbot Technologies LP bought a new stake in shares of OptimizeRx during the 2nd quarter valued at about $44,000. BNP Paribas Financial Markets lifted its stake in shares of OptimizeRx by 119.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after purchasing an additional 2,215 shares during the period. MetLife Investment Management LLC purchased a new stake in OptimizeRx in the first quarter worth about $99,000. Finally, Virtu Financial LLC bought a new stake in OptimizeRx in the first quarter worth $112,000. Hedge funds and other institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.